PT  - JOURNAL ARTICLE
AU  - Wynberg, Elke
AU  - Han, Alvin X.
AU  - van Willigen, Hugo D.G.
AU  - Verveen, Anouk
AU  - van Pul, Lisa
AU  - Maurer, Irma
AU  - van Leeuwen, Ester M.
AU  - van den Aardweg, Joost G.
AU  - de Jong, Menno D.
AU  - Nieuwkerk, Pythia
AU  - Prins, Maria
AU  - Kootstra, Neeltje A.
AU  - de Bree, Godelieve J.
AU  - ,
TI  - Inflammatory profiles are associated with long COVID up to 6 months after illness onset: a prospective cohort study of individuals with mild to critical COVID-19
AID  - 10.1101/2023.06.14.23291395
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.14.23291395
4099  - http://medrxiv.org/content/early/2023/06/15/2023.06.14.23291395.short
4100  - http://medrxiv.org/content/early/2023/06/15/2023.06.14.23291395.full
AB  - Background After initial COVID-19 disease, immune dysregulation may persist and drive post-acute sequelae of COVID-19 (PASC). We described longitudinal trajectories of cytokines in adults up to 6 months following SARS-CoV-2 infection and explored early predictors of PASC.Methods RECoVERED is a prospective cohort of individuals with laboratory-confirmed SARS-CoV-2 infection between May 2020 and June 2021 in Amsterdam, the Netherlands. Serum was collected at weeks 4, 12 and 24 of follow-up. Monthly symptom questionnaires were completed from month 2 after illness onset onwards; lung diffusion capacity (DLCO) was tested at 6 months. Cytokine concentrations were analysed by human magnetic Luminex screening assay. We used a linear mixed-effects model to study log-concentrations of cytokines over time, assessing their association with socio-demographic and clinical characteristics that were included in the model as fixed effects.Results 186/349 (53%) participants had ≥2 serum samples and were included. Of these, 101 (54%: 45/101[45%] female, median age 55 years [IQR=45-64]) reported PASC at 12 and 24 weeks after illness onset. We included 37 reference samples (17/37[46%] female, median age 49 years [IQR=40-56]). PASC was associated with raised CRP and abnormal diffusion capacity with raised IL10, IL17, IL6, IP10 and TNFα at 24 weeks in the multivariate model. Early (0-4 week) IL-1β and BMI at illness onset were predictive of PASC at 24 weeks.Conclusions Our findings indicate that immune dysregulation plays an important role in PASC pathogenesis, especially among those individuals with reduced pulmonary function. Early IL-1β shows promise as predictors of PASC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Netherlands Organization for Health Research and Development (ZonMw) [10150062010002 to M.D.d.J. and 10430072110003 to G.J.d.B] and the Public Health Service of Amsterdam [R&D grants in 2021 and 2022 to M.P.]. The funders had no role in study design, data collection, data analysis, data interpretation or data reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from each study participant. The study design was approved by the local ethics committee of the Amsterdam UMC (Medisch Ethische Toetsingscommissie [METC]; NL73759.018.20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors